top of page

Understanding Bladder Cancer: An Infographic Overview

Bladder cancer is the most common malignancy of the urinary tract. As of 2022, Bladder Cancer had an incidence of 614,298 patients worldwide, and 220,596 patients succumbed to the disease. While the therapeutic approach to it remained largely unchanged for many years, recent clinical progress has paved the way towards a novel era of diagnosis and management of the disease, with several special designations and two very recent approvals by the US FDA.

In December 2023, the FDA approved enfortumab vedotin-ejfv + pembrolizumab for first-line patients with locally advanced/metastatic (la/m) Urothelial Cancer (UC). This combination was previously granted accelerated approval in April 2023 for patients with la/m UC who are ineligible for cisplatin-containing chemotherapy. Further in March 2024, nivolumab + cisplatin + gemcitabine was approved for frontline treatment of unresectable/metastatic cisplatin-eligible UC patients.

The current infographic provides a concise overview of the evolving treatment landscape of Bladder Cancer, spotlighting both established and emerging therapeutic approaches.

Join us in recognizing May as Bladder Cancer Awareness Month by exploring the evolving strategies in the fight against this disease.


bottom of page